AbbVie’s patent-aggressive US strategy for flagship Humira pays off, as judge dismisses lawsuit alleging anticompetitive activity
AbbVie has long fiercely protected its flagship Humira — the world’s bestselling drug — with a patent raincoat perhaps as durable as a Mackintosh. And while it has made a series of moves for a post-Humira future, notably the $63 billion acquisition of Allergan, a US judge has ruled in favor of the company against allegations that it engaged in anticompetitive conduct to elbow out rivals in the United States.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.